atai Launches Revixia to Develop Salvinorin A
Yesterday, atai Life Sciences formally announced the launch of Revixia Life Sciences. We say ‘formally’ because the program was outlined in public messaging prior to yesterday’s press release, including in atai’s S-1 filing in advance of the company’s IPO (note: three members of the Psilocybin Alpha team discussed the filing’s contents, including Revixia, on Business Trip in June).
The wholly owned subsidiary will develop Salvinorin A to treat “a variety of mental health disorders,” according to the release. The molecule is derived from Salvia divinorum, a plant from the mint family that has long been used in spiritual and curative treatments by the Mazatec people.
Prominent psychedelic researcher Bryan Roth expressed doubt over the potential therapeutic value of Salvinorin A, exclaiming: